← Leaderboards
Nithya Ramnath
Roswell Park Cancer Institute Corp
$1,296,527
Attributed
$1,801,696
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $413K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,801,696 · 2
VA$0 · 4
By mechanism
R33$1,010,339 · 1
R21$791,357 · 1
I01$0 · 4
Top collaborators
- Sunitha Nagrath3 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Anna Bianchi-Smiraglia$2,303,673
- Walter J Storkus$19,974,413
- Elizabeth Repasky$12,725,917
- Eugene Yu$11,511,700
- Paul D Soloway$7,315,048
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of LungResponseNon-Small-Cell Lung CarcinomaTumorVeteransAmericanCessation Of LifeCancer EtiologyAffectBloodBaseDiagnosisComplexPublic Health RelevanceResistanceNeoplastic CellGenesMediatingToxic EffectImmunotherapyCellsClinical TrialsPharmaceutical Preparations
Grant awards (19)
Repositioning Immunotherapy in Veterans with Lung Cancer$0
I01 · FY2025 · VA · contact PI
Repositioning Immunotherapy in Veterans with Lung Cancer$0
I01 · FY2024 · VA · contact PI
Influence of T Cell Clonality on PD-1 Blockade in Non-Small Cell Lung Cancer$0
I01 · FY2021 · VA · contact PI
Induction of Senescence using Dexamethasone to re-sensitize NSCLC to anti-PD1 therapy$0
I01 · FY2021 · VA · contact PI
Influence of T Cell Clonality on PD-1 Blockade in Non-Small Cell Lung Cancer$0
I01 · FY2020 · VA · contact PI
Induction of Senescence using Dexamethasone to re-sensitize NSCLC to anti-PD1 therapy$0
I01 · FY2020 · VA · contact PI
Induction of Senescence using Dexamethasone to re-sensitize NSCLC to anti-PD1 therapy$0
I01 · FY2019 · VA · contact PI
Influence of T Cell Clonality on PD-1 Blockade in Non-Small Cell Lung Cancer$0
I01 · FY2019 · VA · contact PI
High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug Testing$333,698
R33 · FY2018 · CA
Influence of T Cell Clonality on PD-1 Blockade in Non-Small Cell Lung Cancer$0
I01 · FY2018 · VA · contact PI
High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug Testing$332,977
R33 · FY2017 · CA
Influence of T Cell Clonality on PD-1 Blockade in Non-Small Cell Lung Cancer$0
I01 · FY2017 · VA · contact PI
High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug Testing$343,664
R33 · FY2016 · CA
The role of Vitamin D metabolism in Non-Small Cell Lung Cancer$0
I01 · FY2012 · VA · contact PI
The role of Vitamin D metabolism in Non-Small Cell Lung Cancer$0
I01 · FY2011 · VA · contact PI
The role of Vitamin D metabolism in Non-Small Cell Lung Cancer$0
I01 · FY2011 · VA · contact PI
A Phase I/II Clinical Trial of Intravenous (I.V.) Calcitriol with Fixed Doses of$378,381
R21 · FY2009 · CA · contact PI
A Phase I/II Clinical Trial of Intravenous (I.V.) Calcitriol with Fixed Doses of$214,343
R21 · FY2008 · CA · contact PI
A Phase I/II Clinical Trial of Intravenous (I.V.) Calcitriol with Fixed Doses of$198,633
R21 · FY2008 · CA · contact PI